Literature DB >> 11450624

[A case of primary zopiclone dependence].

I Kahlert1, M Brüne.   

Abstract

MEDICAL HISTORY: A 59-year-old female patient reported an increasing intake of up to 20 pills of zopiclone per day (150 mg) during the past 3 years. The dose increase was associated with euphoria and subjectively improved fitness. The patient suffered from anxiety and inner restlessness when trying to discontinue the medication, as well as from fatigue and forgetfulness when on medication. The medical history was free of psychiatric disorders and abuse of psychoactive substances. CLINICAL
FINDINGS: Apart from mild attention and concentration deficits with a mildly depressed mood the psychiatric findings were normal. COURSE AND TREATMENT: Consistent with the preliminary diagnosis of a primary non-benzodiazepine dependence (zopiclone), after withdrawal of zopiclone the patient suffered from inner restlessness and psychomotor agitation, vague abdominal pain, and hypertension. The symptoms subsided after administration and subsequent gradual discontinuation of diazepam.
CONCLUSION: Zopiclone dependence has repeatedly been reported in patients with pre-existing substance-related addictions, and in patients with other psychiatric disorders. Primary zopiclone dependence may be regarded as rare. Despite the low dependence potential of non-benzodiazepine hypnotics, the indication of prescription should be thoroughly considered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11450624     DOI: 10.1055/s-2001-14488

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  [Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007].

Authors:  F Hoffmann; W Scharffetter; G Glaeske
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

2.  [High usage of zolpidem and zopiclone. Cross-sectional study using claims data].

Authors:  F Hoffmann; M Pfannkuche; G Glaeske
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.